Outcomes of allogeneic stem cell transplantation for patients with t(6:9) AML- A strong case for allogeneic stem cell transplantation in first complete remission

Br J Haematol. 2020 Jun;189(5):806-808. doi: 10.1111/bjh.16478. Epub 2020 Jan 30.

Authors

Maximilian Stahl¹, Martin S Tallman¹

Affiliation

¹ Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

PMID: 31999852
DOI: 10.1111/bjh.16478

No abstract available

Keywords: AML; allogeneic stem cell transplantation; complete remission.

Publication types

Comment

MeSH terms

Chromosomal Proteins, Non-Histone
Hematopoietic Stem Cell Transplantation*
Humans
Leukemia, Myeloid, Acute* / therapy
Nuclear Pore Complex Proteins
Oncogene Proteins
Poly-ADP-Ribose Binding Proteins
Remission Induction

Substances

Chromosomal Proteins, Non-Histone
DEK protein, human
NUP214 protein, human
Nuclear Pore Complex Proteins
Oncogene Proteins
Poly-ADP-Ribose Binding Proteins